Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 13
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
STX0206
NCT00724503
2.
Comparing Hepatic Intra-Arterial Injection of Yttrium-90 Microspheres Versus Fluorouracil (5FU) in Colorectal Cancer Metastatic to the Liver Only
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
Sir-Spheres1
NCT00199173
3.
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
CTCT 06-11
NCT00493883
4.
Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-Resectable Primary HCC
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
NMRC - AHCC05
NCT00712790
Last Modified:
1/18/2008
 
First Published:
6/1/2002
5.
Hepatic Artery-Directed Internal Radiation Therapy Using Yttrium-90 Microspheres (TheraSphere®) in Patients With Unresectable Hepatocellular Carcinoma (Primary Liver Cancer)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
PCI-IRB-0611014
PCI-IRB-000656, PCI-IRB-000871, NCI-V02-1701, NCT00039078
Last Modified:
8/26/2008
 
First Published:
2/12/2007
6.
Phase II Study of Selective Internal Radiotherapy With Yttrium Y 90 Microspheres, Selective External Radiotherapy With Tomotherapy, and Fluorouracil in Patients With Unresectable, Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Over 18
Other
CCCGHS-SIRT-SERT
NCT00436267
7.
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
STX 0106
NCT00503867
Last Modified:
9/13/2007
 
First Published:
9/12/2007
8.
Phase II Study of Yttrium Y 90 Glass Microspheres (TheraSphere®) in Patients With Unresectable Hepatocellular Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
NU-1365-001
NU 1365-001, NCT00530010
Last Modified:
6/9/2008
 
First Published:
9/14/2007
9.
Phase II Study of Yttrium Y 90 Glass Microspheres (TheraSphere®) in Patients With Unresectable, Metastatic Intrahepatic Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
NU-1365-002
NU 1365-002, NCT00532740
10.
TheraSphere for the Treatment of Liver Metastases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
G040148
NCT00511862
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute